MedTrace Logo

Evolution of CMV Antiviral T-cell Immunity Over the Next Six Months Initiation of Treatment With Belatacept.

NCT05708534 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 28

Last updated 2026-05-22

No results posted yet for this study

Summary

Belatacept inhibits T cell activation by blocking the costimulatory signal. In kidney transplantation, it limits the use of anticalcineurins while ensuring a satisfactory level of immunosuppression.

Conditions

  • Kidney Transplant Infection

Interventions

DRUG

Belatacept

Switching from anticalcineurins to belatacept in a cohort of kidney transplant recipients seropositive for CMV

Sponsors & Collaborators

  • University Hospital, Rouen

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-14
Primary Completion
2026-05-13
Completion
2027-05-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05708534 on ClinicalTrials.gov